vida: extract claims from 2026-05-02-glp1-psychiatric-safety-signal-195pct-mdd-risk-cohort

- Source: inbox/queue/2026-05-02-glp1-psychiatric-safety-signal-195pct-mdd-risk-cohort.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap.md

@@ -11,9 +11,16 @@ sourced_from: health/2025-truveta-ispor-glp1-discontinuation-reasons.md
 scope: correlational
 sourcer: Truveta Research
 supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation"]
+related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure"]
 ---
 
 # GLP-1 discontinuation is 12 percent higher among patients with psychiatric medication history creating an access-adherence trap where highest-need populations have lowest persistence
 
 Truveta's analysis of real-world GLP-1 discontinuation patterns found that patients with a history of psychiatric medication use are 12 percent more likely to discontinue GLP-1 therapy compared to those without psychiatric history. This creates a compounding access-adherence trap: patients with co-occurring mental health and metabolic conditions face the highest obesity burden and metabolic disease risk, yet are systematically less likely to both access GLP-1s (due to income and coverage barriers documented in KFF data) AND maintain therapy when they do gain access. The psychiatric comorbidity effect operates independently of income, age, and other comorbidity factors, suggesting a distinct mechanism—potentially related to medication burden, side effect tolerance, or behavioral health system fragmentation. This finding reveals that the population most likely to benefit from GLP-1 therapy (those with multiple chronic conditions including mental health disorders) faces a double barrier: structural access limitations followed by adherence failure even when access is achieved.
+
+
+## Supporting Evidence
+
+**Source:** Community-based cohort study via PMC systematic review
+
+The 195% MDD risk finding provides a mechanistic explanation for why psychiatric comorbidity predicts GLP-1 discontinuation. If GLP-1 increases depression risk in predisposed individuals, patients with existing psychiatric conditions would be both more likely to experience adverse mood effects and more likely to discontinue treatment. This creates a clinical paradox: the populations who might benefit most from GLP-1's addiction benefits may also face the highest psychiatric risk.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -67,3 +67,10 @@ NCT06548490 is the first Phase 2 RCT testing semaglutide for treatment-refractor
 **Source:** Hendershot et al., JAMA Psychiatry 2025
 
 First RCT evidence: 26-week trial of 108 AUD+obesity patients showed semaglutide+CBT reduced heavy drinking days 41.1%, with NNT 4.3 versus 7+ for approved AUD medications. Blood-alcohol biomarkers corroborated self-reports. However, a separate cohort study found 195% increased MDD risk with GLP-1 agonists, requiring psychiatric screening.
+
+
+## Extending Evidence
+
+**Source:** PMC systematic review + JAMA Psychiatry RCT
+
+The dual psychiatric profile of GLP-1s suggests the mesolimbic dopamine modulation mechanism has broader effects than previously understood. While the mechanism successfully reduces substance use (41.1% reduction in heavy drinking days, NNT 4.3), the same reward salience reduction may create depression risk through reduced hedonic response. This implies GLP-1 behavioral health deployment requires psychiatric monitoring infrastructure, not just addiction treatment protocols.

domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md

@@ -31,3 +31,10 @@ Meta-analysis confirms semaglutide as best-performing agent for alcohol reductio
 **Source:** Qeadan F et al., Addiction 2025
 
 Real-world observational data from 817,309 AUD patients (5,621 with GLP-1 RA) shows 50% lower alcohol intoxication rates (IRR 0.50, 95% CI 0.40-0.63) over 24 months, consistent with Hendershot RCT findings. Effect maintained across T2DM (IRR 0.51), obesity (IRR 0.58), and combined conditions (IRR 0.58) subgroups. Provides population-scale corroboration of the VTA dopamine mechanism hypothesis, though observational confounding limits causal inference.
+
+
+## Challenging Evidence
+
+**Source:** PMC systematic review + JAMA Psychiatry RCT (N=108)
+
+Community-based cohort study found 195% increased risk of major depressive disorder among individuals treated with liraglutide or semaglutide. This psychiatric safety signal creates a clinical tension: GLP-1 reduces addiction craving (NNT 4.3 for AUD) but may increase depression risk in predisposed individuals. The mechanistic hypothesis is that GLP-1 reduces reward salience broadly—beneficial for addiction but potentially harmful for mood regulation. Researchers now emphasize comprehensive psychiatric assessment before initiating GLP-1 therapy in populations at elevated psychiatric risk.

inbox/archive/health/2026-05-02-glp1-psychiatric-safety-signal-195pct-mdd-risk-cohort.md

@@ -7,10 +7,13 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: research-summary
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-02
 priority: high
 tags: [GLP-1, semaglutide, depression, MDD, psychiatric-safety, alcohol-use-disorder, behavioral-health, safety-signal]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content